Table 3

Association of CD44/CD24 immunophenotypes with clinicopathological variables in 69 SGMN patients
CD44/CD24 profilea
+/+ +/− −/+ −/− Total p
Gender Male 2 (2.9%) 17 (24.6%) 4 (5.8%) 5 (7.2%) 28 (40.6%) 0.091
Female 12 (17.4%) 19 (27.5%) 0 (0.0%) 10 (14.5%) 41 (59.4%)
Age ≤ 60 8 (11.6%) 22 (31.9%) 2 (2.9%) 9 (13.0%) 41 (59.4%) 0.967
> 60 6 (8.7%) 14 (20.3%) 2 (2.9%) 6 (8.7%) 28 (40.6%)
Smoking intake Yes 3 (4.3%) 12 (17.4%) 2 (2.9%) 6 (8.7%) 23 (33.3%) 0.554
No 11 (15.9%) 24 (34.8%) 2 (2.9%) 9 (13.0%) 46 (66.7%)
Alcohol intake Yes 2 (2.9%) 7 (10.1%) 3 (4.3%) 2 (2.9%) 14 (20.3%) 0.831
No 12 (17.4%) 29 (42.0%) 1 (1.4%) 14 (21.7%) 55 (79.7%)
PLSb Majorc 7 (10.1%) 27 (39.1%) 4 (5.8%) 4 (5.8%) 42 (60.9%) 0,005
Minord 7 (10.1%) 9 (13.0%) 0 (0.0%) 11 (15.9%) 27 (39.1%)
Tumor size T1/T2 4 (5.8%) 24 (34.8%) 3 (4.3%) 11 (15.9%) 42 (60.8%) 0.023
T3/T4 10 (14.5%) 12 (17.4%) 1 (1.4%) 4 (5.8%) 27 (39.1%)
Clinical Stage I / II 2 (2.9%) 17 (24.6%) 0 (0.0%) 6 (8.7%) 25 (36.2%) 0.098
III / VI 12 (17.4%) 19 (27.5%) 4 (5.8%) 9 (13.0%) 44 (63.8%)
Treatment Surgery 3 (4.3%) 11 (15.9%) 1 (1.4%) 4 (5.8%) 19 (27.5%) 0.807
Sur. Adj T.e 11 (15.9%) 25 (36.2%) 3 (4.3%) 11 (15.9%) 50 (72.5%)
Metastasis No 8 (11.6%) 24 (34.8%) 2 (2.9%) 9 (13.0%) 43 (62.3%) 0.790
Yes 6 (8.7%) 12 (17.4%) 2 (2.9%) 6 (8.7%) 26 (37.7%)
Loco-regional No 8 (11.6%) 25 (36.2%) 2 (2.9%) 10 (14.5%) 45 (65.2%) 0.711
Recurrence Yes 6 (8.7%) 11 (15.9%) 2 (2.9%) 5 (7.2%) 24 (34.8%)
Lymph node No 9 (13.0%) 34 (49.3%) 1 (1.4%) 14 (20.3%) 58 (84.0%) 0,011
Yes 5 (7.2%) 2 (2.9%) 3 (4.3%) 1 (1.4%) 11 (16.0%)
Death No 11 (15.9%) 25 (36.2%) 3 (4.3%) 9 (13.0%) 48 (69.6%) 0.556
Yes 3 (4.3%) 11 (15.9%) 1 (1.4%) 6 (8.7%) 21 (30.4%)

a +/+ cases CD44+/CD24+; +/− cases CD44+/CD24- and −/− cases CD44-/CD24-; −/− cases CD44-/CD24+. bPLS: Primary Lesion Site; cMajor: Major Salivary Glands (Parotid Gland/Submandibular Gland/Sublingual Gland); dMinor; Minor Salivary Glands; eSur. Adj. T.: Surgery with adjuvant therapy. Statistically significant difference (<0.05) by Fisher’s exact test (two variables) or χ2 (three or more variables) tests.

Soave et al.

Soave et al. Diagnostic Pathology 2013 8:29   doi:10.1186/1746-1596-8-29

Open Data